Abstract
Multiple Sclerosis is an inflammatory and degenerative disorder involving the central nervous system. It primarily affects young adults and may result in significant long-term disability. The most common initial presentation is relapsing remitting, followed by a chronic progressive course. In a small number of patients the disease tends to be progressive from onset. Multiple sclerosis has traditionally been described as a demylinating disorder. There is now overwhelming evidence pointing to a very significant degenerative component. Current treatment options include immunomodulating and immunosuppressive agents as well as monoclonal antibodies and target the inflammatory component of the disease resulting in significant reduction in relapses, decrease in MRI lesion load and a modest effect on disability. There are several other biological agents being developed which target different aspects of the immunopathology of multiple sclerosis. This article will review the agents currently used in the treatment of MS and also discuss agents currently under development.
Keywords: Multiple sclerosis, demyelination, degeneration, immunosupression, MRI, trials, interferon, antibodies, relapses
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Multiple Sclerosis: Current and Future Treatment Options
Volume: 7 Issue: 4
Author(s): S. Rizvi
Affiliation:
Keywords: Multiple sclerosis, demyelination, degeneration, immunosupression, MRI, trials, interferon, antibodies, relapses
Abstract: Multiple Sclerosis is an inflammatory and degenerative disorder involving the central nervous system. It primarily affects young adults and may result in significant long-term disability. The most common initial presentation is relapsing remitting, followed by a chronic progressive course. In a small number of patients the disease tends to be progressive from onset. Multiple sclerosis has traditionally been described as a demylinating disorder. There is now overwhelming evidence pointing to a very significant degenerative component. Current treatment options include immunomodulating and immunosuppressive agents as well as monoclonal antibodies and target the inflammatory component of the disease resulting in significant reduction in relapses, decrease in MRI lesion load and a modest effect on disability. There are several other biological agents being developed which target different aspects of the immunopathology of multiple sclerosis. This article will review the agents currently used in the treatment of MS and also discuss agents currently under development.
Export Options
About this article
Cite this article as:
Rizvi S., Multiple Sclerosis: Current and Future Treatment Options, Endocrine, Metabolic & Immune Disorders - Drug Targets 2007; 7 (4) . https://dx.doi.org/10.2174/187153007782794380
DOI https://dx.doi.org/10.2174/187153007782794380 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulatory Mechanisms of Calcineurin Phosphatase Activity
Current Medicinal Chemistry Old and New Gasotransmitters in the Cardiovascular System: Focus on the Role of Nitric Oxide and Hydrogen Sulfide in Endothelial Cells and Cardiomyocytes
Current Pharmaceutical Biotechnology Biomarkers in Lone Atrial Fibrillation-An Additional ‘Fine Tuning’ of Risk?
Current Pharmaceutical Design Endothelin Signalling in the Cardiac Myocyte and its Pathophysiological Relevance
Current Vascular Pharmacology Iodinated Contrast Media in Diagnostic Imaging: Cardiovascular Side Effects
Current Pharmacogenomics and Personalized Medicine TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Current Drug Targets Autophagy and Cell Death in Caenorhabditis elegans
Current Pharmaceutical Design Editorial (Thematic Issue: Cardiac Imaging in the Diagnosis of Coronary Artery Disease: A Comprehensive Overview of Various Imaging Modalities)
Current Medical Imaging Chemotherapy and Targeted Agents for Elderly Women with Advanced Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Human Induced Pluripotent Stem Cells for Inherited Cardiovascular Diseases Modeling
Current Stem Cell Research & Therapy Targets for Anti-T. cruzi Drugs in the Post-Genomic Era
Current Enzyme Inhibition Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Chaperone Therapy: New Molecular Therapy for Protein Misfolding Diseases with Brain Dysfunction
Current Bioinformatics Challenges in Chagas Disease Drug Discovery: A Review
Current Medicinal Chemistry Cancer Proteomics: New Horizons and Insights into Therapeutic Applications
Current Proteomics The Role of Transesophageal Echocardiography in the Intraoperative Period
Current Cardiology Reviews Cardiovascular Imaging in Thromboembolic Risk Stratification for Atrial Fibrillation: Recent Patents and Current Practice
Recent Patents on Medical Imaging Changes in the Expression of the Alzheimers Disease-Associated Presenilin Gene in Drosophila Heart Leads to Cardiac Dysfunction
Current Alzheimer Research Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches
Current Pharmaceutical Design Mitochondrial and Nuclear Genes of Mitochondrial Components in Cancer
Current Genomics